GDTC CytoMed Therapeutics
- 2.070
- -0.050-2.36%
CytoMed Therapeutics News
CytoMed Therapeutics Announces Upcoming AGM
CytoMed Diversifies Into Regenerative Medicine After Research Collaboration With Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration
SINGAPORE / ACCESSWIRE / March 20, 2024 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company that focuses on utilizing its licensed propriet
CytoMed Therapeutics Has Obtained Board Approval To Launch, Pilot Program To Isolate And Cryo-Store Peripheral Blood Mononuclear Cells For And As A Reward To Loyal Shareholders Of CytoMed On Complimentary Basis, The Program Will Commence On June 1, 2024
CytoMed Therapeutics Has Obtained Board Approval To Launch, Pilot Program To Isolate And Cryo-Store Peripheral Blood Mononuclear Cells For And As A Reward To Loyal Shareholders Of CytoMed On Complimen
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to
CytoMed Therapeutics Limited Announces Research Collaboration With Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair
SINGAPORE, March 04, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersNanoString Technologies (NASDAQ:NSTG) stock moved upwards by 26.9% to $0.15 during Friday's pre-market session. The company's market cap stands at $7.0 million. TC BioPharm (Holdings) (NASDAQ:T
OGEN, SSP and ZENV Among Mid-day Movers
Tenax Therapeutics, Equillium Among Healthcare Movers
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersSocietal CDMO (NASDAQ:SCTL) shares moved upwards by 23.4% to $0.57 during Wednesday's pre-market session. The market value of their outstanding shares is at $59.7 million. Apollomics (NASDAQ:AP
CytoMed Therapeutics Receives Patent in Malaysia for Its Prospective Cancer Therapy
CytoMed Therapeutics (GDTC) said Monday that its chimeric antigen receptor gamma delta T cell technology targeting solid and hematological tumors has been approved for a patent by the Intellectual Pro
Cytomed Therapeutics Announced That The Intellectual Property Corporation Of Malaysia Has Granted A Patent For Its Chimeric Antigen Receptor Gamma Delta T Cell Technology, Which Targets Solid And Hematological Tumors
Cytomed Therapeutics Announced That The Intellectual Property Corporation Of Malaysia Has Granted A Patent For Its Chimeric Antigen Receptor Gamma Delta T Cell Technology, Which Targets Solid And Hema
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
The Company now has exclusive rights to a Malaysia, US and China patent.
Athira Pharma, Sera Prognostics Among Healthcare Movers
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersCyclo Therapeutics (NASDAQ:CYTH) stock rose 34.1% to $2.2 during Wednesday's after-market session. The market value of their outstanding shares is at $50.0 million. Cingulate (NASDAQ:CING) shar
One CytoMed Therapeutics Insider Raised Stake By 46% In Previous Year
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology
CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-
Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target
Benchmark analyst Bruce Jackson reiterates CytoMed Therapeutics (NASDAQ:GDTC) with a Speculative Buy and maintains $5 price target.
CytoMed Therapeutics Limited Reports 1H Results
CytoMed Therapeutics Reports 1H 2023 Financial Report And Provides Corporate Update; Cash And Cash Equivalents: As Of June 30, 2023, The Company Had Cash And Cash Equivalents Of $7.72M
Financial Results for the Six Months Ended June 30, 2023Net Loss: For the six months ended June 30, 2023, the Company's unaudited net loss amounted to S$1.16M ($860,695) excluding expenses related to
CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference
SINGAPORE, Nov. 14, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary techno
Analysis
Price Target
No Data
